GCTK - יחס חוב להיוון בספרים glucotrack.com

GlucoTrack, Inc. (GCTK) price action is under pressure from industry leaders and a lack of research funding. The ratio of debt obligations to balance sheet equity demonstrates current leverage, where the value of 0.00 captures this metric. The brand's success relies on FDA approval and the accuracy of its needle-free sensors. High growth potential is driven by the sale of software and consumables, which create a stable cash cow.

This indicator measures the proportion of borrowed funds relative to equity, allowing for an assessment of financial stability without market distortions. The metric reveals the company's dependence on creditors amid the high cost of developing non-invasive systems. By analyzing the debt-to-equity coverage ratio, an investor can see the impact of regulatory delays on the liability structure. An increase in the coefficient signals a critical level of debt load, while declining values confirm the fundamental viability of the GlucoTrack, Inc. (GCTK) business.